Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Beginning Cash Position: ¥594 Mil (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SHSE:600613

55 GF Score

Price ¥4.99

GF Value ¥5.41

Valuation Fairly Valued

5 Warning Signs

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

What is Shanghai Shenqi Pharmaceutical Investment Management Co Beginning Cash Position?

Shanghai Shenqi Pharmaceutical Investment Management Co SHSE:600613 +1.63% 55 Beginning Cash Position is ¥594 Mil as of Mar. 2026. GuruFocus rates SHSE:600613 with a GF Score™ of 55/100 and a GF Value™ of ¥5.41 (Fairly Valued). The stock has 5 warning signs investors should review.

Shanghai Shenqi Pharmaceutical Investment Management Co's Beginning Cash Position for the quarter that ended in Mar. 2026 was ¥594 Mil.

Shanghai Shenqi Pharmaceutical Investment Management Co's quarterly Beginning Cash Position declined from Sep. 2025 (¥682 Mil) to Dec. 2025 (¥611 Mil) and declined from Dec. 2025 (¥611 Mil) to Mar. 2026 (¥594 Mil).

Shanghai Shenqi Pharmaceutical Investment Management Co's annual Beginning Cash Position increased from Dec. 2023 (¥655 Mil) to Dec. 2024 (¥714 Mil) and increased from Dec. 2024 (¥714 Mil) to Dec. 2025 (¥779 Mil).

Try GuruFocus Premium free for 7 days

Unlock GF Score, GF Value, 30-Y financials, and pro screeners.

Get Started →

Shanghai Shenqi Pharmaceutical Investment Management Co Beginning Cash Position Related Terms

Shanghai Shenqi Pharmaceutical Investment Management Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Shanghai Shenqi Pharmaceutical Investment Management Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Shenqi Pharmaceutical Investment Management Co Beginning Cash Position Chart

Shanghai Shenqi Pharmaceutical Investment Management Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Beginning Cash Position

Get a 7-Day Free Trial

481.35

493.74

654.57

714.29

779.39

Shanghai Shenqi Pharmaceutical Investment Management Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Beginning Cash Position	Get a 7-Day Free Trial															779.39	775.21	681.54	611.06	594.09

55GF Score

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SHSE:600613

Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

Shanghai Shenqi Pharmaceutical Investment Management Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Frequently Asked Questions Learn more about Beginning Cash Position →

What does a Beginning Cash Position of ¥594 Mil mean?

Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) has a Beginning Cash Position of ¥594 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors.

Is Shanghai Shenqi Pharmaceutical Investment Management Co's Beginning Cash Position too high?

Shanghai Shenqi Pharmaceutical Investment Management Co's current Beginning Cash Position is ¥594 Mil. Overall, Shanghai Shenqi Pharmaceutical Investment Management Co has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Shanghai Shenqi Pharmaceutical Investment Management Co's Beginning Cash Position compare to LLY and JNJ?

Shanghai Shenqi Pharmaceutical Investment Management Co's Beginning Cash Position of ¥594 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beginning Cash Position for a Drug Manufacturers company?

A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beginning Cash Position mean?

A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. Shanghai Shenqi Pharmaceutical Investment Management Co's current Beginning Cash Position is ¥594 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Shanghai Shenqi Pharmaceutical Investment Management Co stock overvalued right now?

Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.41, compared to a current price of ¥4.99 — trading 7.8% below its estimated fair value. The current Beginning Cash Position is ¥594 Mil. Shanghai Shenqi Pharmaceutical Investment Management Co's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beginning Cash Position calculated?

Beginning Cash Position is calculated from a company's financial statements. For Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613), the current Beginning Cash Position is ¥594 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be undervalued. The current stock price of ¥4.99 is trading 7.8% below its estimated GF Value™ of ¥5.41. GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Fairly Valued.

Key valuation signals for SHSE:600613:

Beginning Cash Position: ¥594 Mil
GF Value™: ¥5.41 vs. price of ¥4.99 (7.8% below fair value)
GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →